利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

117 条记录 (耗时 0.027 秒)

    VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES
    65.
    发明授权
    VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES 有权
    用于初级疫苗接种的囊状葡萄膜炎病毒（VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES）

    公开(公告)号：EP2794637B1

    公开(公告)日：2017-06-21

    申请号：EP12859997.4

    申请日：2012-12-21

    申请人： The University Of Western Ontario

    发明人： KANG, Chil-Yong ,  KIM, Gyoung Nyoun

    IPC分类号： A61K39/12

    CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

    摘要： The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

    摘要翻译： 本发明涉及水泡性口炎病毒（VSV）基质（M）蛋白突变体。 一个突变体M蛋白质包括在21位改变为谷氨酸的甘氨酸，在111位亮氨酸改变为苯丙氨酸，并且在第51位甲硫氨酸改变为精氨酸。另一种M蛋白质突变体包括在位置改变为谷氨酸的甘氨酸 22和第48和51位的甲硫氨酸变为精氨酸。另一VSV M蛋白突变体包括在22位改变为谷氨酸的甘氨酸，在位置110改变为苯丙氨酸，在位置110改变为精氨酸， 本发明还涉及具有这些M突变体的重组VSV（rVSV）和基于具有本发明的M突变体的rVSV的疫苗。 这些具有突变M的新rVSV显着减毒并丧失毒力，包括神经毒力，并且能够诱导针对感兴趣抗原的免疫应答。 另外，具有第一个描述的M突变体的rVSV血清型印第安纳州能够在31℃有效复制，并且在37℃或更高的温度下能够复制不良或不能复制。

    Compounds for treatment of ischemic injury
    69.
    发明公开
    Compounds for treatment of ischemic injury 审中-公开
    Verbindungen zur BehandlungischämischerVerletzungen

    公开(公告)号：EP2584040A1

    公开(公告)日：2013-04-24

    申请号：EP11462021.4

    申请日：2011-10-17

    申请人： Pharmahungary 2000 Kft.

    发明人： Csont, Tamás ,  Varga, Zoltán ,  Ferdinándy, Péter

    IPC分类号： C12N15/113 ,  A61P9/10 ,  A61K31/7088

    CPC分类号： A61K31/713 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/141

    摘要： The present invention relates to a method for preparing specific microRNA (miRNA) compounds by using test ischemia-reperfusion, test preconditioning and test postconditioning of biological samples, use of the miRNA compounds and nucleic acid encoding them in the preparation of pharmaceutical compositions having cytoprotective and/or anti-ischemic effect in ischemic (e.g. cardiac) diseases and said miRNAs and pharmaceutical compositions comprising them for use in related diseases and methods for treatment thereof.

    摘要翻译： 本发明涉及通过使用测试缺血再灌注，生物样品的测试预处理和测试后处理来制备特异性微小RNA（miRNA）化合物的方法，使用miRNA化合物和编码它们的核酸来制备具有细胞保护性的药物组合物， /或缺血性（例如心脏）疾病中的抗缺血作用，以及包含它们的所述miRNA和药物组合物用于相关疾病及其治疗方法。